Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
Fiche publication
Date publication
octobre 2018
Journal
Cancer chemotherapy and pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ZANETTA Sylvie
Tous les auteurs :
Martin N, Isambert N, Gomez-Roca C, Goeldner RG, Zanetta S, Sadrolhefazi B, de Mont-Serrat H, Campone M, Delord JP
Lien Pubmed
Résumé
Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer.
Mots clés
Afatinib, Diarrhea, HER2-positive cancer, Trastuzumab
Référence
Cancer Chemother. Pharmacol.. 2018 Oct 22;: